Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients Post published:August 12, 2022 Post category:Press Release
MindMed Strengthens Board with Appointment of Two New Independent Directors Post published:August 12, 2022 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS Post published:August 12, 2022 Post category:Press Release
MindMed Reports Second Quarter 2022 Financial Results and Business Highlights Post published:August 11, 2022 Post category:Press Release
Psilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders Post published:August 10, 2022 Post category:Press Release
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Post published:August 9, 2022 Post category:Press Release
PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications Post published:August 9, 2022 Post category:Press Release
Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle Post published:August 9, 2022 Post category:Press Release
Field Trip Health Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 16, 2022, at 8:30 AM ET Post published:August 8, 2022 Post category:Press Release
MindMed Board of Directors Approves Reverse Share Split Post published:August 5, 2022 Post category:Press Release